Modelos de datos seleccionados

Debe iniciar sesión para seleccionar modelos de datos para descargar o realizar un análisis.

12 Resultados de la búsqueda.
Relevancia Evaluación Nuevo primero Antiguo primero

Investigational product (Liver) GSK study Chronic Coronary Heart Disease NCT00799903

- 4/1/18 - 1 formulario, 2 itemgroups, 8 items, 1 idioma
Itemgroups: Liver event during treatment period, Liver event after treatment period
Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: Investigational product (Liver)

Concomitant Medication SirTac NCT02936388 - Concomitant Medication

- 3/12/17 - 1 formulario, 1 itemgroup, 12 items, 1 idioma
Itemgroup: Concomitant Medication
Study part: Concomitant Medication. A Randomized Phase II Trial of Transarterial Radioembolisation With Yttrium-90 (SIRT) in Comparison to Transarterial Chemoembolisation With Cisplatin (TACE) in Patients With Liver Metastases From Uveal Melanoma. Provided by Prof. Dr. Ulrich Keilholz, Charité – University of medicine Berlin. EudraCT-Nummer: 2014-002439-32. NCT02936388.

End of Therapy SirTac NCT02936388 - End of Therapy

- 28/11/17 - 1 formulario, 1 itemgroup, 12 items, 1 idioma
Itemgroup: Therapy end
Study part: End of Therapy. A Randomized Phase II Trial of Transarterial Radioembolisation With Yttrium-90 (SIRT) in Comparison to Transarterial Chemoembolisation With Cisplatin (TACE) in Patients With Liver Metastases From Uveal Melanoma. Provided by Prof. Dr. Ulrich Keilholz, Charité – University of medicine Berlin. EudraCT-Nummer: 2014-002439-32. NCT02936388.

Gastroenterology activity recording, University Hospital Cologne

- 22/4/17 - 1 formulario, 10 itemgroups, 34 items, 1 idioma
Itemgroups: Gastroenterology service, New patient, Follow-up visit, Termination, Chemotherapy, Administration, Counseling, Diagnostics, Procedure, Chemotherapy
Hospital Routine Documentation Subform at the University Hospital Cologne. Original Form name: Leistungserf_Gastro

27920_Visit 1 EpimiRNA Study D Vagal Nerve Stimulation NCT02359188 - Visit 1 EpimiRNA Study D Vagal Nerve Stimulation NCT02359188

- 19/12/17 - 1 formulario, 7 itemgroups, 21 items, 1 idioma
Itemgroups: Administrative data, First blood sample, Attachment of ear electrode of tVNS device, Test meal, Second blood sample, Adverse events and comments, Signature physician
NCT02359188 Influence of Transcutaneous Vagal Nerve Stimulation on Expression of microRNA, Cytokines, Chemokines and Neuropeptides as Well as Cerebral Resting State and Gastric Motility Quellenangabe: Dr. Sebastian Bauer Philipps-Universität Marburg

27924_Visit 2 EpimiRNA Study D Vagal Nerve Stimulation NCT02359188 - Visit 2 EpimiRNA Study D Vagal Nerve Stimulation NCT02359188

- 19/12/17 - 1 formulario, 8 itemgroups, 25 items, 1 idioma
Itemgroups: Administrative data, First blood sample, tVNS / sham-tVNS, Test meal, Second blood sample, MRI, Adverse events and comments, Signature physician
NCT02359188 Influence of Transcutaneous Vagal Nerve Stimulation on Expression of microRNA, Cytokines, Chemokines and Neuropeptides as Well as Cerebral Resting State and Gastric Motility Quellenangabe: Dr. Sebastian Bauer Philipps-Universität Marburg

Visit 2 EpimiRNA Study D Vagal Nerve Stimulation NCT02359188

- 5/12/17 - 1 formulario, 8 itemgroups, 25 items, 1 idioma
Itemgroups: Administrative data, First blood sample, tVNS / sham-tVNS, Test meal, Second blood sample, MRI, Adverse events and comments, Signature physician
NCT02359188 Influence of Transcutaneous Vagal Nerve Stimulation on Expression of microRNA, Cytokines, Chemokines and Neuropeptides as Well as Cerebral Resting State and Gastric Motility Quellenangabe: Dr. Sebastian Bauer Philipps-Universität Marburg

WTZ-GIST-09-01 (Imatinib + LBH589) Dosage administration record 2009-011417-24 DRKS00000657 - WTZ-GIST-09-01 (Imatinib + LBH589) Dosage administration record 2009-011417-24

- 15/12/16 - 1 formulario, 2 itemgroups, 20 items, 1 idioma
Itemgroups: Dosage administration, Contribution of study medication
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors WTZ-GIST-09-01 (EudraCT number: 2009-011417-24; German Clinical Trials Register: DRKS00000657) was approved by the institutional ethics committees of the two participating centers and the German Federal Regulatory Drug Agency (BfArM; 4035954).

WTZ-GIST-09-01 (Imatinib + LBH589) Concomitant Therapies 2009-011417-24 DRKS00000657 - WTZ-GIST-09-01 (Imatinib + LBH589) Concomitant Therapies 2009-011417-24

- 2/12/16 - 1 formulario, 1 itemgroup, 8 items, 1 idioma
Itemgroup: Concomitant Therapies
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors WTZ-GIST-09-01 (EudraCT number: 2009-011417-24; German Clinical Trials Register: DRKS00000657) was approved by the institutional ethics committees of the two participating centers and the German Federal Regulatory Drug Agency (BfArM; 4035954).

WTZ-GIST-09-01 (Imatinib + LBH589) Cycle 1 Pharmacokinetics 2009-011417-24 DRKS00000657 - WTZ-GIST-09-01 (Imatinib + LBH589) Cycle 1 Pharmacokinetics 2009-011417-24

- 23/11/16 - 1 formulario, 1 itemgroup, 7 items, 1 idioma
Itemgroup: Pharmacokinetics (PK)
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors WTZ-GIST-09-01 (EudraCT number: 2009-011417-24; German Clinical Trials Register: DRKS00000657) was approved by the institutional ethics committees of the two participating centers and the German Federal Regulatory Drug Agency (BfArM; 4035954).

WTZ-GIST-09-01 (Imatinib + LBH589) Prior Antineoplastic Treatment 2009-011417-24 DRKS00000657 - WTZ-GIST-09-01 (Imatinib + LBH589) Prior Antineoplastic Treatment 2009-011417-24

- 23/11/16 - 1 formulario, 2 itemgroups, 14 items, 1 idioma
Itemgroups: Prior Antineoplastic Treatment - Chemotherapy, Prior Antineoplastic Treatment - Surgery
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors WTZ-GIST-09-01 (EudraCT number: 2009-011417-24; German Clinical Trials Register: DRKS00000657) was approved by the institutional ethics committees of the two participating centers and the German Federal Regulatory Drug Agency (BfArM; 4035954).

REGIMS Registry Baseline - Baseline Main Sheet

- 20/9/21 - 3 formularios, 25 itemgroups, 116 items, 2 idiomas
Itemgroups: Ein-Ausschlusskriterien, Patientendaten, Krankheitsspezifische Angaben, EDSS-Score vor 12 Monaten, Heutige Scores der Funktionssysteme, Frühere verlaufsmodifizierende MS-Therapien, Aktuelle MS-Therapie, WeitereErkrankungen, Herz- / Kreislauferkrankungen, Stoffwechselerkrankungen, Infektionserkrankungen, Gastrointestinale Erkrankungen, Neurologische / Psychiatrische Erkrankungen, Allergien, Urogenitale Erkrankungen, Autoimmunerkrankungen, Blutbild / Labor, Allgemeine Symptome, Operation, Krebserkrankungen, Welche Therapien wurden aufgrund der Krebserkrankung durchgeführt?, Andere Erkrankung, Keine Vorerkrankungen aus diesen obigen Krankheitsgruppen/Erkrankungen bekannt, Schwangerschaft, Biologisches Material (z.B. Blut)
Baseline items for semantic analysis of the Multiple sclerosis immunotherapy registry REGIMS of the Institute of Epidemiology and Social Medicine of the University Hospital Münster provided by Prof. Dr. Klaus Berger and Dr. Maximov Stanislav.

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial